Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Istradefylline for Parkinson Disease Cognitive Impairment
NCT05333549Phase 2Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Jul 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Istradefylline in Parkinson's disease (PD), sponsored by Virginia Commonwealth University. Primary endpoint: Change in Executive Function - Card Sort at 26 weeks. Started Jul 2022; status: completed.
02
Drugs
Istradefylline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05333549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05333549.